{"schema_version":"secwatch.filing_event.v1","accession":"0001746473-23-000036","form_type":"8-K","ticker":"PLRX","cik":"0001746473","company_name":"PLIANT THERAPEUTICS, INC.","filed_at":"2023-06-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.360051+00:00","generated_at":"2026-06-14T05:08:57.713179+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Pliant Therapeutics shareholders elect directors, approve say-on-pay, ratify auditor at 2023 annual meeting","bullets":["All three Class III director nominees (Coulie, Crowell, Bruhn) elected; Coulie received 48.3M for, 1.1M withhold.","Non-binding say-on-pay proposal approved with 47.99M for, 1.38M against, 36k abstain.","Ratification of Deloitte & Touche LLP as auditor for FY2023 passed with 54.81M for, 12.5k against.","Broker non-votes totaled 5,432,103 shares on director election and say-on-pay."],"urls":{"canonical":"https://secwatch.observer/filing/0001746473-23-000036","json":"https://secwatch.observer/filing/0001746473-23-000036.json","markdown":"https://secwatch.observer/filing/0001746473-23-000036.md","text":"https://secwatch.observer/filing/0001746473-23-000036.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1746473/000174647323000036/0001746473-23-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1746473/000174647323000036/plrx-20230607.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T05:08:57.713179+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"09dc1f43c8887d06ea7ae8e129167d9d78b0630c","claim":"PLIANT THERAPEUTICS, INC. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for fiscal year ending December 31, 2023 at the 2023-06-07 meeting.","evidence_excerpt":"Proposal 3: The Company’s stockholders ratified the selection of Deloitte & Touche LLP as the Company’s independent registered public accounting firm. The votes cast at the Annual Meeting were as follows: For Against Abstain 54,811,068 12,512 19,255","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647323000036/0001746473-23-000036-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-07"}],"fact_type":"shareholder_vote"},{"claim_id":"9d8d83a42328f54c624d62f8bd010c1e0bba656b","claim":"PLIANT THERAPEUTICS, INC. shareholders approved Election of Bernard Coulie, M.D., Ph.D., Gayle Crowell and Suzanne Bruhn, Ph.D. as Class III directors at the 2023-06-07 meeting.","evidence_excerpt":"Proposal 1: The Company’s stockholders approved the election of the aforementioned Class III directors recommended for election at the Annual Meeting. The Company’s stockholders voted for the Class III directors as follows: Nominee For Withhold Bernard Coulie, M.D., Ph.D. 48,316,375 1,094,357 Gayle Crowell 39,771,872 9,638,860 Suzanne Bruhn, Ph.D. 39,735,738 9,674,994 The broker non-votes for Proposal 1 totaled 5,432,103 shares of common stock.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647323000036/0001746473-23-000036-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-07"}],"fact_type":"shareholder_vote"},{"claim_id":"c8f19b66c3313f929d6d7d3d51876ce22ef4cb20","claim":"PLIANT THERAPEUTICS, INC. shareholders approved Approval, by non-binding advisory vote, of the compensation of the Company’s named executive officers at the 2023-06-07 meeting.","evidence_excerpt":"Proposal 2: The Company’s stockholders approved, by non-binding advisory vote, the compensation of the Company’s named executive officers, as follows: For Against Abstain 47,994,590 1,379,942 36,200 The broker non-votes for Proposal 2 totaled 5,432,103 shares of common stock.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/1746473/000174647323000036/0001746473-23-000036-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"say on pay"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2023-06-07"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}